Your browser doesn't support javascript.
loading
Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies.
Ch'ng, Sydney; Uyulmaz, Semra; Carlino, Matteo S; Pennington, Thomas E; Shannon, Kerwin F; Rtshiladze, Michael; Stretch, Jonathan R; Nieweg, Omgo E; Varey, Alexander H R; Hsiao, Edward; Kapoor, Rony; Pires da Silva, Ines; Lo, Serigne N; Spillane, Andrew J; Scolyer, Richard A; Long, Georgina V; Hong, Angela M; Saw, Robyn P M; Thompson, John F; Menzies, Alexander M.
Afiliación
  • Ch'ng S; Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Sydney Head & Neck Cancer Institute, Chris O'Brien Lifehouse Cancer Centre, Camperdown, Australia. Electronic address: sydney.chng@sydney.edu.au.
  • Uyulmaz S; Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Sydney Head & Neck Cancer Institute, Chris O'Brien Lifehouse Cancer Centre, Camperdown, Australia.
  • Carlino MS; Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia; Westmead Hospital, Westmead, New South Wales, Australia.
  • Pennington TE; Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Mater Hospital, North Sydney, New South Wales, Australia.
  • Shannon KF; Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Sydney Head & Neck Cancer Institute, Chris O'Brien Lifehouse Cancer Centre, Camperdown, Australia.
  • Rtshiladze M; Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Mater Hospital, North Sydney, New South Wales, Australia.
  • Stretch JR; Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Mater Hospital, North Sydney, New South Wales, Australia.
  • Nieweg OE; Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Mater Hospital, North Sydney, New South Wales, Australia.
  • Varey AHR; Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia; Westmead Hospital, Westmead, New South Wales, Australia.
  • Hsiao E; Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Royal North Shore Hospital, St Leonards, New South Wales, Australia.
  • Kapoor R; Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Mater Hospital, North Sydney, New South Wales, Australia; Royal North Shore Hospital, St Leonards, New South Wales, Australia.
  • Pires da Silva I; Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia.
  • Lo SN; Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Spillane AJ; Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia; Mater Hospital, North Sydney, New South Wales, Australia; Royal North Shore Hospital, St Leonards, New South
  • Scolyer RA; Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia; Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
  • Long GV; Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia; Mater Hospital, North Sydney, New South Wales, Australia; Royal North Shore Hospital, St Leonards, New South
  • Hong AM; Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia; Mater Hospital, North Sydney, New South Wales, Australia; Department of Radiation Oncology, Chris O'Brien Li
  • Saw RPM; Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Mater Hospital, North Sydney, New South Wales, Australia.
  • Thompson JF; Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Mater Hospital, North Sydney, New South Wales, Australia.
  • Menzies AM; Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia; Mater Hospital, North Sydney, New South Wales, Australia; Royal North Shore Hospital, St Leonards, New South
Eur J Cancer ; 153: 8-15, 2021 08.
Article en En | MEDLINE | ID: mdl-34126335
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Inhibidores de Puntos de Control Inmunológico / Inmunoterapia / Melanoma Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Eur J Cancer Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Inhibidores de Puntos de Control Inmunológico / Inmunoterapia / Melanoma Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Eur J Cancer Año: 2021 Tipo del documento: Article